CCNE1 and cancer: The catalytic activity of CDK2-CyclinE complexes is hyperactivated in several cancers by Cyclin E amplification, or a loss-of-function mutation of FBXW7, a ubiquitin ligase for Cyclin E degradation, although CDK2 mutations are rare in human cancers49.